ESR1 and prostate cancer: For this AI, it was reported that it affects the viability of ER+ breast cancer cells [20] and presents promising anti-cancer properties in lung, liver, colon and prostate cancer cell lines by inducing cell cycle arrest, apoptosis and necrosis as well as DNA damage, and also by inhibiting the DNA damage response [31].